nad and glp 1 Effects of Glucagon-Like Peptide-1 on Oxidative Stress Nrf2 Signaling Boost Your Health with GLP-1

Calcified Tissue International

Revised: May 2025 PRINCIPAL DISPLAY PANEL - 3 mL Pen Carton NDC 0024-5761-05 Rx only SOLIQUA 100/33 (insulin glargine and lixisenatide) injection For Single Patient Use Only 100 units/mL and 33 mcg/mL With each unit of insulin glargine, the pen also delivers 0.33 mcg of lixisenatide Only for Doses from 15 to 60 Units For subcutaneous injection only Dispense with the medication guide Solution for injection in a SoloStar disposable insulin delivery device Never remove medication using a syringe Do not mix with other insulins Use only if solution is clear and colorless with no particles visible Five 3 mL prefilled pens (15 mL total) Dispense in this sealed carton *Needles not included (see back panel) sanofi Biological Products Related to Soliqua Find detailed information on biosimilars for this medication

Frequently Asked Questions Does anxiety from GLP-1s go away

This article clarifies who should avoid GLP-1 medications, necessary screening, and alternative treatment options for high-risk patients

Heise T, DeVries JH, Urva S, Li J, Pratt EJ, Thomas MK, Mather KJ, Karanikas CA, Dunn J, Haupt A et al (2023) Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes

Figure 1 shows the most relevant aspects of the benefits/risks profile of GLP-1 RAs